KLP Kapitalforvaltning
TSHA icon

KLP Kapitalforvaltning’s Taysha Gene Therapies TSHA Stock Holding History

KLP Kapitalforvaltning’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
47,800
+18,500
+63% +$109K ﹤0.01% 1690
2026
Q1 		$131K Hold
29,300
– – ﹤0.01% 1974
2025
Q4 		$161K Buy
+29,300
New +$142K ﹤0.01% 1912

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

KLP Kapitalforvaltning's TSHA Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Taysha Gene Therapies (TSHA) stake by 63% in Q2 2026, buying an estimated $109K and bringing the position to 47,800 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1690.

KLP Kapitalforvaltning first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • KLP Kapitalforvaltning held 47,800 shares of Taysha Gene Therapies worth $326K as of Q2 2026.
  • KLP Kapitalforvaltning bought 18,500 Taysha Gene Therapies shares in Q2 2026, an estimated $109K.
  • Taysha Gene Therapies made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1690 holding.
  • KLP Kapitalforvaltning first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.